Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative High-Risk Wilms Tumor Project: Application of Array-Based Methods and Next Generation Sequencing to Identify Candidate Molecular Targets for High-Risk Wilms Tumors
- To assess genomic gains and losses in samples from high-risk Wilms tumor patients,
including 50 favorable histology Wilms tumors that relapse (RFHWT) and 50 anaplastic
Wilms tumors (UHWT) using a high-density genetic platform to survey for recurrent copy
number variations and allelic imbalances.
- To define transcription patterns within these samples using a high-throughput platform
for global gene expression.
- To define DNA methylation patterns within these samples using a high-throughput
- To identify genetic mutations involved in the pathogenesis of Wilms tumor and in the
development of relapse and anaplasia through the study of these samples using
next-generation sequencing tools.
- To facilitate the integration of the above databases and allow meaningful access by
investigators through the infrastructure provided by TARGET, including its data portal
and associated caBIG tool.
OUTLINE: This is a multicenter study.
Archived tumor tissue samples are analyzed for DNA copy number determination, gene
expression, DNA methylation, and genomic re-sequencing by array-based methods, including PCR
analysis, methylation-specific reverse transcriptase-PCR (RT-PCR), and quantitative RT-PCR.
Genomic gains and losses in high-risk Wilms tumor
Elizabeth J. Perlman, MD
Ann & Robert H Lurie Children's Hospital of Chicago